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[Iodine-131]6-beta-iodomethylnorcholesterol (NP-59) visualization of adrenocortical carcinoma is unusual.
We describe a 17-year-old female with virilization and elevated plasma testosterone, dehydroepiandrosterone
sulfate (DHEAS) and aldosterone. Magnetic resonance imaging disclosed a 9-cm right adrenal mass. NP-59
adrenal scanning displayed unilateral uptake of tracer and no visualization of the contralateral adrenal gland.
Exploratory laparotomy revealed adrenocortical carcinoma. Subsequent immunohistochemical studies
confirmed that the tumor was capable of producing a mixture of steroids, including testosterone, DHEAS
and aldosterone. Visualization of an adrenal tumor on NP-59 scintiscan is an unusual finding, which cannot
exclude the possibility of malignancy. [J Formos Med Assoc 2006;105(4):340–345]
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Adrenocortical carcinoma (ACC) is a rare disorder,
with an estimated incidence of 0.6–2.0 cases per
million.1 In general, approximately half of these
tumors are functioning, that is, secreting excess
hormones and producing endocrinologic symp-
toms and signs, which lead to their discovery.2
Among functioning ACCs, the most common hor-
monal abnormality is hypersecretion of both
glucocorticoids and androgens (42%), followed
by hypersecretion of glucocorticoids alone (41%)
and hypersecretion of androgens alone (10%).3
The prognosis of ACC is usually poor, and the
life expectancy of afflicted patients depends large-
ly on correct diagnosis leading to prompt treat-
ment.2
Several diagnostic methods have been in-
troduced to determine whether an adrenal mass
is benign or malignant. NP-59 ([I-131]6-beta-
iodomethylnorcholesterol) nuclear scintigraphy,
a noninvasive diagnostic modality that can pro-
vide information about the functional status of
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the adrenal glands, has been utilized for this pur-
pose. On NP-59 scintigraphy, benign adrenal
adenomas typically exhibit a concordant imaging
pattern, with uptake of the radiotracer on the side
of the known adrenal mass and lack of visualiza-
tion of the contralateral gland.4,5 However, ACCs
are usually not visualized, as the amount of radio-
tracer uptake by these tumors is usually insuffi-
cient to permit adequate imaging.6
In this report, we describe a virilizing ACC,
which displayed a concordant imaging pattern
on NP-59 scintigraphy. This tumor was found to
be capable of producing dehydroepiandrosterone
sulfate (DHEAS), testosterone and aldosterone
both in vivo and in vitro.
Case Report
A 17-year-old female was referred for evaluation
of primary amenorrhea. She had been a good ath-
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ng/mL; DHEAS > 1105 μg/dL, normal, 40–394 μg/
dL). Serum aldosterone was also elevated (579
pg/mL; normal, 37.5–240 pg/mL), but plasma
renin level was normal (13.21 pg/mL; normal,
2.5–21.4 pg/mL). Early morning cortisol was 6.4
μg/dL (normal, 5–25 μg/dL), which increased to
31.3 μg/dL 60 minutes after an intravenous injec-
tion of 250 μg of adrenocorticotropic hormone
(ACTH)-(1-24) (Synacthen; Novartis Pharma AG,
Basle, Switzerland). Serum 17-hydroxyprogester-
one level was 4.73 ng/mL, which increased to 8.64
ng/mL 60 minutes after intravenous 250 μg ACTH-
(1-24), thereby excluding the possibility of atten-
uated congenital adrenal hyperplasia.
Magnetic resonance imaging of the adrenal
glands showed an oval-shaped multicystic tumor,
9 × 5 × 8.4 cm in size, in the right suprarenal re-
gion. The tumor showed low signal intensity on
T1-weighted scan, and mild enhancement on
T2-weighted scan (Figure 1). On dexamethasone-
modified NP-59 adrenal scintiscan, mildly in-
creased activity in the right suprarenal area was
noted at 48 hours, and significant accumulation
of tracer together with complete lack of visuali-
zation of the contralateral gland was noted at 72
hours (Figure 2), favoring a concordant pattern of
tumor imaging.
Exploratory laparotomy was performed with
removal of the right adrenal tumor. Pathologic ex-
amination of the resected tumor confirmed ACC.
The postoperative course was uneventful, and re-
placement of hydrocortisone was not required. Six
days postoperatively, plasma testosterone had de-
creased to 0.21 ng/mL, plasma aldosterone to 306
lete since childhood and had no major medical
disorders. On physical examination, she was tall
and lean, with clinical evidence of virilism, includ-
ing hirsutism of the face and back, clitoromegaly,
and deep voice. Breast development was Tanner
stage 1 and Cushingoid features were not evident.
Blood pressure was 100/65 mmHg. Biochemical
data were within normal limits and serum potas-
sium was 4.7 mmol/L (normal, 3.4–4.7 mmol/L).
Endocrine tests revealed a plasma estradiol
level of 110 pg/mL (normal, 25–120 pg/mL), fol-
licle-stimulating hormone (FSH) of 1.81 mIU/mL
(normal, 5–30 mIU/mL), luteinizing hormone
(LH) of 15.72 mIU/mL (normal, 2–200 mIU/mL),
and prolactin of 7.87 ng/mL (normal, 3.0–26.0 ng/
mL). Serum testosterone and DHEAS were both
far above the detection limit of our laboratory
(testosterone > 14.40 ng/mL, normal, 0.09–0.86
Figure 1. Magnetic resonance imaging of the adrenal glands shows
an oval-shaped multicystic tumor, 9 × 5 × 8.4 cm in size, in the right
suprarenal region. The tumor shows: (A) low signal intensity on T1-
weighted scan (arrow); and (B) mild enhancement on T2-weighted
scan (arrow).
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Figure 2.
Dexametha-
sone-modified
NP-59 adrenal
scintiscan shows
unilateral
uptake by the
tumor (arrow)
and complete
lack of
visualization of
the contralateral
adrenal gland
(posterior view).
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pg/mL, and morning serum cortisol was 27.9
μg/dL (plasma DHEAS not available). Treatment
with mitotane, 500 mg three times a day, was start-
ed 1 week after surgery and continued thereafter.
One month after surgery, the patient experienced
menarche, and her menstrual periods were sub-
sequently regular. At the 1-year follow-up, she was
apparently healthy and hirsutism was much
improved. There was no clinical evidence of meta-
stasis. Hormone profiles were all within normal
ranges (testosterone, 0.65 ng/mL; DHEAS, 200 μg/
dL; aldosterone, 128 pg/mL).
Histopathologic examination
The resected adrenal tumor measured 11 × 10 × 5
cm and weighed 265 g. Microscopic examination
showed pleomorphic tumor cells, containing hy-
perchromatic bizarre nuclei and intensely eosi-
nophilic cytoplasm (Figure 3). The tumor exhibited
three pathologic features of the Weiss criteria:7 high
nuclear grade; > 75% eosinophilic cytoplasm; and
diffuse architecture of tumor structure. It was,
therefore, classified as an ACC.
Immunohistochemical staining was per-
formed using the labeled streptavidin-biotin
method (LSAB 2 Kit; DAKO Corp, Carpinteria, CA,
USA). Antibodies were diluted as follows: aldos-
terone (1:50; Biogenesis, Poole, Dorset, UK); tes-
tosterone (1:25; Biogenesis); and DHEAS (1:30;
BiosPacific, Emeryville, CA, USA). On microscop-
ic examination, the tumor showed focal immuno-
reactivity (about 10%) to aldosterone. Well-stained
cells tended to be arranged in thin trabeculae or
ribbon patterns, and their nuclei were vesicular
and uniform in size, whereas weakly-stained cells
grew in sheets or in a pleomorphic sarcoma-like
pattern (Figure 4A). In contrast to aldosterone, im-
munoreactivity to both testosterone and DHEAS
was diffuse and intense throughout the whole
specimen (Figures 4B and 4C).
Discussion
This rare case of virilizing ACC showed concor-
dant uptake on NP-59 scintiscan. Our review of
the English literature revealed only 10 previous
reports of primary ACC with a concordant NP-59
imaging pattern, including three patients with
Cushing’s syndrome (one associated with hir-
sutism),8–10 six patients with primary aldosteron-
ism,11–14 and one patient with increased urinary
excretion of androsterone and DHEA15 (Table).16
All of these tumors secreted excess hormones bio-
chemically and produced clinical endocrinologic
symptoms and signs, and some were also described
as being well differentiated on histologic exami-
nation of the resected tissues.9–11,15 Most (9/11) of
these tumors were found at a lower stage () stage
2), and most (7/11) of the patients remained free
of recurrence during the follow-up period after tu-
mor resection. Thus, both the functional status of
the tumor and the degree of differentiation of tu-
mor cells appear to be important factors in deter-
mining visualization on NP-59 scintigraphy, with
the degree of differentiation of tumor cells, i.e.
grade of malignancy, probably being the more im-
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Figure 3.
Microscopic
section
(hematoxylin
& eosin stain)
shows
pleomorphic
tumor cells
with intensely
eosinophilic
cytoplasm and
hyperchromatic
bizarre nuclei
(arrows): (A) ×
100; (B) × 250.
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portant factor. The findings in this case, a pre-
dominantly testosterone and DHEAS secreting
virilizing ACC of relatively low grade malignancy
(stage 2), which remained free of recurrence dur-
ing 34 months of follow-up, support this hypo-
thesis.
Hypertension and hypokalemia are the most
common clinical features of primary aldosteron-
ism. However, despite a high serum aldosterone
level, our patient was normotensive and normo-
kalemic, as has been reported in a previous case.17
Since hypertension is usually followed by hypo-
kalemia in the evolving course of primary aldoster-
onism, our patient might have been in the very
early stage of primary aldosteronism, displaying
no symptoms or signs of mineralocorticoid excess
clinically, which is characteristic of the normoka-
lemic type.18
Steroidogenesis in human ACC is unique, and
has been described either as low efficiency steroid
production or abnormal steroidogenesis.19 In this
case, extremely high plasma DHEAS and testo-
B  A C
Figure 4. (A) Focal immunostaining to aldosterone (diaminobenzidine [DAB], brown, × 100). Differing from that of aldosterone, the immunoreactivity to
both (B) testosterone and (C) DHEAS was diffuse and intense (DAB, brown, × 100).
Table.   NP-59 scan positive primary adrenocortical carcinomas reported in the English literature
Age/Sex Hypersecretory state
Tumor Staging at Postoperative
Reference #
size (cm) presentation* survival
30/F Cushing’s syndrome 8 2 Died at 9 mo 08
66/F Cushing’s syndrome 5 2 Alive at 21 mo 09
66/F Cushing’s syndrome (with hirsutism) 5 2 Alive at 66 mo 10
47/F Primary aldosteronism 3  1 Alive at 32 mo 11
67/F Primary aldosteronism 7  2 Alive at 17 mo 12
43/M Primary aldosteronism 5 2 Alive at 18 mo 13
54/F Primary aldosteronism 110 3 Alive at 6 mo 13
42/M Primary aldosteronism 7 2 Alive at 35 mo 14
54/F Primary aldosteronism 11 0 3 Alive at 2 mo 14
43/F Incidentaloma, with elevated androsterone &
DHEA excretion in urine 22 0 2 Died at 11 mo 15
17/F Virilism, with increased testosterone,
DHEAS & aldosterone secretion 11 0 2 Alive at 34 mo Present case
*Staging: 1, < 5 cm; 2, > 5 cm and confined to the adrenal gland; 3, locoregional invasion or spread to local lymph nodes; and 4, distant meta-
stasis.16
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sterone levels were documented, which were ap-
parently responsible for clinical virilization of the
patient. DHEAS is a well-known adrenal androgen
produced exclusively by the adrenals, whereas
only a minimal amount of testosterone is produced
in normal adrenals.20 It has been suggested that
excess testosterone production in virilizing adre-
nocortical tumors derives mainly from periphe-
ral conversion of adrenal androgens, including
DHEA, DHEAS, delta(5)-androstenediol, and del-
ta(4)-androstenedione.21 In this case, immunohis-
tochemical staining demonstrated that testoster-
one could be produced directly from ACC cells.
This finding is in accordance with a previous
case report in which the ACC cells were capable
of synthesizing testosterone.22 The activity of 17`-
hydroxysteroid dehydrogenase, the enzyme re-
sponsible for converting androstenedione to tes-
tosterone, has been shown to be 50-fold higher
in virilizing adrenal adenomas than in normal
adrenals.23 However, its activity in virilizing ACCs
has not yet been studied; therefore, whether a
similar mechanism exists and is responsible for
the observed increased secretion of testosterone
in virilizing ACCs remains to be determined. Fur-
ther research regarding the activity or expression
of 17`-hydroxysteroid dehydrogenase on ACCs
is needed to provide insight into the steroidogenic
pathways of these tumors.
In this case, immunostaining to aldosterone
appeared to be more intense in tumor cells with
less nuclear atypia and with a trabecular or cord-
like pattern. This histologic finding has been de-
scribed as a characteristic of functioning ACCs.24
However, since there is much structural overlap
between functioning and nonfunctioning tumors,
tumor functionality cannot be predicted based on
histology alone.24 In contrast to that of aldosterone,
immunostaining to DHEAS and testosterone was
diffuse and intense even in areas of nuclear pleo-
morphism and of sarcoma-like pattern. This dis-
crepancy may reflect the diversity and complexity
of the steroidogenic pathways of ACCs.
In summary, this case of virilization due to a
large ACC exhibited intense unilateral uptake on
NP-59 adrenal scan. The tumor was shown to be
capable of producing a mixture of steroids, includ-
ing testosterone, DHEAS and aldosterone, both in
vivo and in vitro. This case illustrates the potential
pitfall of assuming that all ACCs are unable to up-
take sufficient radiotracer for imaging on NP-59
scanning. Visualization of an adrenal tumor on NP-
59 scintiscan cannot exclude the possibility of
malignancy.
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